Aug 22, 2014 at 18:08 | Source: CNBC-TV18
The Competition Commission in India and the US Federal Trade Commission are closely scrutinising the deal to see if there could be any sort of monopolistic situations in the market post this deal and this clearance would be the most crucial.
Aug 22, 2014 at 16:44 | Source: CNBC-TV18
Akshata Deshmukh, Chief Strategist-Trading at Networth Stock Broking is of the view that one may hold Ranbaxy Laboratories with a target of Rs 750-770.
Aug 22, 2014 at 15:37 | Source: Moneycontrol.com
Ranbaxy Laboratories has informed that a meeting of the Equity Shareholders of the Company will be held on September 19, 2014 for considering Scheme of Arrangement providing merger of the Company with Sun Pharmaceutical Industries Limited.
Aug 22, 2014 at 15:36 | Source: CNBC-TV18
Surajit Pal picks Glenmark as his top pharma bet among midcaps.
Aug 22, 2014 at 12:58 | Source: CNBC-TV18
Here are few top buzzing stocks picked by CNBC-TV18's analysts in trade today. We have Shree Renuka, Balrampur Chini, Bajaj Hindustan, Hitachi Home, United Spirits, Nectar Life, Sun Pharma, Ranbaxy and Bank Nifty.
Aug 22, 2014 at 08:57 | Source: CNBC-TV18
Here are top 10 stocks to focus on August 22 - BPCL, IOC, Indian Hotels, Syndicate Bank, Ranbaxy, United Spirits, Tilaknagar Industries, HCC, Gammon India and Ceat.
Aug 22, 2014 at 08:35 | Source: Moneycontrol.com
While specific details of the fine are still awaited, CNBC-TV18 reports the fine by the US Department of Justice could be possibly over violations in its Toansa facility.
Aug 22, 2014 at 08:28 | Source: CNBC-TV18
United Spirits | Gammon India | Ceat | Genus Power | Hotel Leela | Ranbaxy Labs | Mangalore Chemicals and Fertilisers | Larsen and Toubro | Gujarat Alkalies | Arvind | Prakash Industries | NTPC | UPL | NHPC | SJVN and Tilaknagar Industries are stocks, which are in the news today.
Aug 21, 2014 at 16:49 | Source: CNBC-TV18
Hemen Kapadia of KR Choksey Securities is of the view that one may hold Ranbaxy Laboratories.
Aug 21, 2014 at 15:36 | Source: CNBC-TV18
Ashu Madan of Religare Securities is of the view that one may hold Ranbaxy Laboratories.